Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thanks--eom
anything new???? eom
any dd appreciated--authorized? outstanding? is there a Chill on the stock? thanks--eom
IMMU-at 5.00--radar for 5.14 break-they shorted the great news 4 weeks ago from the 6.00's--eom
IMMU-at 5.00--radar for 5.14 break-they shorted the great news 4 weeks ago from the 6.00's--eom
thanks---eom
AMDA-IPO'ed today at 6.00 a share--some info-We are a commercial biomaterial company focused on using our silicon nitride
technology platform to develop, manufacture and sell a broad range of medical
devices. We currently market spinal fusion products and are developing products
for use in total hip and knee joint replacements. We believe
our silicon nitride
technology platform enables us to offer new and transformative products in the
orthopedic and other medical device markets. We believe we are the first and
only company to use silicon nitride in medical applications and over 14,000 of
our silicon nitride spine products have been implanted in patients.
Biomaterials are synthetic or natural materials available in a variety of forms
that are used in virtually every medical specialty. We believe our silicon
nitride biomaterial has superior characteristics compared to commonly used
biomaterials in the markets we are targeting, including polyetheretherketone, or
PEEK, which is the most common biomaterial used for interbody spinal fusion
products. Specifically, we believe our silicon nitride has the following key
attributes: promotion of bone growth; hardness, strength and resistance to
fracture; resistance to wear; non-corrosive; anti-infective properties; and
superior diagnostic imaging compatibility.
We currently market our Valeofamily of silicon nitride interbody spinal fusion
devices in the United States and Europe for use in the cervical and
thoracolumbar areas of the spine. We believe our Valeo devices have a number of
advantages over existing products due to silicon nitride's key characteristics,
resulting in faster and more effective fusion and reduced risk of infection. To
date, the rate of adverse events reported to the U.S. Food and Drug
Administration, or FDA, for our implanted Valeo interbody spinal fusion devices
is 0.1%.
In addition to our silicon nitride-based spinal fusion products, we market a
complementary line of non-silicon nitride spinal fusion products which allows us
to provide surgeons and hospitals with a broader range of products. These
products include three lines of spinal fusion devices and five types of
orthobiologics, which are used by surgeons to help promote bone growth and
fusion in spinal fusion procedures. Although our non-silicon nitride products
have accounted for approximately 70% or more of our product revenues for the
years ended December 31, 2012 and 2011 and the nine months ended September 30,
2013, we believe the continued promotion and potential for adoption of our
silicon nitride products and product candidates, if approved, provides us the
greatest opportunity to grow our business in new and existing markets and
achieve our goal to become a leading biomaterial company.
We are also incorporating our silicon nitride technology into components for use
in total hip and knee replacement product candidates that we are, or plan on,
developing in collaboration with a strategic partner. We believe that our
silicon nitride total hip and knee product candidates will provide competitive
advantages over current products made with traditional biomaterials. We believe
our silicon nitride technology platform can be used for developing products in
other markets and have developed prototypes for use in the dental, sports
medicine and trauma markets. As a result of some of the key characteristics of
our silicon nitride, we also believe our coating technology may be used to
enhance our metal products as well as commercially available metal spinal
fusion, joint replacement and other medical products.
We operate a 30,000 square foot manufacturing facility located at our corporate
headquarters in Salt Lake City, Utah, and we are the only vertically integrated
silicon nitride orthopedic medical device manufacturer in the world. We market
and sell our products to surgeons and hospitals in the United States and select
markets in Europe and South America through our established network of more than
50 independent sales distributors who are managed by our experienced in-house
sales and marketing management team.
---
We were incorporated in Delaware in 1996 under the name Amedica Corp. and have
since changed our name to Amedica Corporation. Effective September 20, 2010, we
acquired all of the outstanding shares of US Spine, Inc. which then became our
wholly-owned subsidiary, which is our only subsidiary. Our principal executive
offices are located at 1885 West 2100 South, Salt Lake City, Utah 84119, and our
telephone number is (801) 839-3500. Our web site address is www.amedicacorp.com.
Read more: http://www.nasdaq.com/markets/ipos/company/amedica-corp-603456-73919#ixzz2tDWFhWvr
AMDA-IPO'ed today at 6.00 a share--some info-We are a commercial biomaterial company focused on using our silicon nitride
technology platform to develop, manufacture and sell a broad range of medical
devices. We currently market spinal fusion products and are developing products
for use in total hip and knee joint replacements. We believe
our silicon nitride
technology platform enables us to offer new and transformative products in the
orthopedic and other medical device markets. We believe we are the first and
only company to use silicon nitride in medical applications and over 14,000 of
our silicon nitride spine products have been implanted in patients.
Biomaterials are synthetic or natural materials available in a variety of forms
that are used in virtually every medical specialty. We believe our silicon
nitride biomaterial has superior characteristics compared to commonly used
biomaterials in the markets we are targeting, including polyetheretherketone, or
PEEK, which is the most common biomaterial used for interbody spinal fusion
products. Specifically, we believe our silicon nitride has the following key
attributes: promotion of bone growth; hardness, strength and resistance to
fracture; resistance to wear; non-corrosive; anti-infective properties; and
superior diagnostic imaging compatibility.
We currently market our Valeofamily of silicon nitride interbody spinal fusion
devices in the United States and Europe for use in the cervical and
thoracolumbar areas of the spine. We believe our Valeo devices have a number of
advantages over existing products due to silicon nitride's key characteristics,
resulting in faster and more effective fusion and reduced risk of infection. To
date, the rate of adverse events reported to the U.S. Food and Drug
Administration, or FDA, for our implanted Valeo interbody spinal fusion devices
is 0.1%.
In addition to our silicon nitride-based spinal fusion products, we market a
complementary line of non-silicon nitride spinal fusion products which allows us
to provide surgeons and hospitals with a broader range of products. These
products include three lines of spinal fusion devices and five types of
orthobiologics, which are used by surgeons to help promote bone growth and
fusion in spinal fusion procedures. Although our non-silicon nitride products
have accounted for approximately 70% or more of our product revenues for the
years ended December 31, 2012 and 2011 and the nine months ended September 30,
2013, we believe the continued promotion and potential for adoption of our
silicon nitride products and product candidates, if approved, provides us the
greatest opportunity to grow our business in new and existing markets and
achieve our goal to become a leading biomaterial company.
We are also incorporating our silicon nitride technology into components for use
in total hip and knee replacement product candidates that we are, or plan on,
developing in collaboration with a strategic partner. We believe that our
silicon nitride total hip and knee product candidates will provide competitive
advantages over current products made with traditional biomaterials. We believe
our silicon nitride technology platform can be used for developing products in
other markets and have developed prototypes for use in the dental, sports
medicine and trauma markets. As a result of some of the key characteristics of
our silicon nitride, we also believe our coating technology may be used to
enhance our metal products as well as commercially available metal spinal
fusion, joint replacement and other medical products.
We operate a 30,000 square foot manufacturing facility located at our corporate
headquarters in Salt Lake City, Utah, and we are the only vertically integrated
silicon nitride orthopedic medical device manufacturer in the world. We market
and sell our products to surgeons and hospitals in the United States and select
markets in Europe and South America through our established network of more than
50 independent sales distributors who are managed by our experienced in-house
sales and marketing management team.
---
We were incorporated in Delaware in 1996 under the name Amedica Corp. and have
since changed our name to Amedica Corporation. Effective September 20, 2010, we
acquired all of the outstanding shares of US Spine, Inc. which then became our
wholly-owned subsidiary, which is our only subsidiary. Our principal executive
offices are located at 1885 West 2100 South, Salt Lake City, Utah 84119, and our
telephone number is (801) 839-3500. Our web site address is www.amedicacorp.com.
Read more: http://www.nasdaq.com/markets/ipos/company/amedica-corp-603456-73919#ixzz2tDWFhWvr
AMDA just now IPO'ed-baragin at 6.00 a share--jmho
AMDA just now IPO'ed-baragin at 6.00 a share--jmho
TLMR-finished the 1st. day IPO with heavy buying at 13.80----going for more today---g/l
TLMR-finished the 1st. day IPO with heavy buying at 13.80----going for more today---g/l
TLMR-big bank IPO this morning--loaded a bunch--g/l--- eom
TLMR-big bank IPO this morning--loaded a bunch--g/l--- eom
GPRK-6.60 x 6.65---14,600 x 1,000-IPO'ed 2 days ago-big oil and gas company--- eom
GPRK-6.60 x 6.65---14,600 x 1,000-IPO'ed 2 days ago-big oil and gas company--- eom
GPRK-at 6.55--vey low volume so far--just IPO'ed 2 days ago---eom
GPRK-at 6.55--vey low volume so far--just IPO'ed 2 days ago---eom
GPRK-some info-In Colombia, following our successful acquisitions of Winchester, Luna and Cuerva in early 2012, we have an asset base of 10 hydrocarbon blocks where we were able to increase average production to 6,075 boepd in the first nine months of 2013, an increase of 89% (on a pro forma basis, giving effect to our Colombian acquisitions) as compared to the first nine months of 2012. As of December 31, 2012, we had net proved reserves of 6.6 mmboe in Colombia. Furthermore, according to the D&M Brazil and Colombia Reserves Report, as of June 30, 2013, net proved reserves for certain new discoveries made in Colombia since December 31, 2012 resulted in an additional 2.4 mmboe of net proved reserves
GPRK-some info-In Colombia, following our successful acquisitions of Winchester, Luna and Cuerva in early 2012, we have an asset base of 10 hydrocarbon blocks where we were able to increase average production to 6,075 boepd in the first nine months of 2013, an increase of 89% (on a pro forma basis, giving effect to our Colombian acquisitions) as compared to the first nine months of 2012. As of December 31, 2012, we had net proved reserves of 6.6 mmboe in Colombia. Furthermore, according to the D&M Brazil and Colombia Reserves Report, as of June 30, 2013, net proved reserves for certain new discoveries made in Colombia since December 31, 2012 resulted in an additional 2.4 mmboe of net proved reserves
GPRK-at 6.35--IPO'ed last Friday-big oil company-undervalued imho--g/l
GPRK-at 6.35--IPO'ed last Friday-big oil company-undervalued imho--g/l
RSOL-Cowen and Company is boosting its price target on Real Goods Solar (Nasdaq: RSOL) from $3.50 up to $5, while maintaining an Outperform rating on the stock.
Analyst Robert Stone noted Real Good Solar's recent announcement to co-develop seven solar projects totaling 4.5MW in Vermont with Green Lantern Capital. Construction is slated to begin in summer with completion expected by November. On January 3, 2014, RSOL announced plans for four projects in Massachusetts totaling 3.5MW. Construction is set to begin in March and be completed in June 2014. These two announcements equate to 40% of the 20.1MW of commercial projects we project for 2014.
Real Good Solar's joint venture with Altus Power America Management should provide up to $150 million of commercial funding for the projects.
While Stone's FY14 outlook is unchanged, the analyst lowered Q413 and Q114 loss expectations to 6 cent per share each with sales of $33 million and $27 million, respectively.
For an analyst ratings summary and ratings history on Real Goods Solar click here. For more ratings news on Real Goods Solar click here.
Real Goods Solar closed at $3.77 last Friday, with a 52 week range of $0.82 to $7.17.
Copyright 2014, Street Insider News Provided by Acquire Media Corporation
RSOL-Cowen and Company is boosting its price target on Real Goods Solar (Nasdaq: RSOL) from $3.50 up to $5, while maintaining an Outperform rating on the stock.
Analyst Robert Stone noted Real Good Solar's recent announcement to co-develop seven solar projects totaling 4.5MW in Vermont with Green Lantern Capital. Construction is slated to begin in summer with completion expected by November. On January 3, 2014, RSOL announced plans for four projects in Massachusetts totaling 3.5MW. Construction is set to begin in March and be completed in June 2014. These two announcements equate to 40% of the 20.1MW of commercial projects we project for 2014.
Real Good Solar's joint venture with Altus Power America Management should provide up to $150 million of commercial funding for the projects.
While Stone's FY14 outlook is unchanged, the analyst lowered Q413 and Q114 loss expectations to 6 cent per share each with sales of $33 million and $27 million, respectively.
For an analyst ratings summary and ratings history on Real Goods Solar click here. For more ratings news on Real Goods Solar click here.
Real Goods Solar closed at $3.77 last Friday, with a 52 week range of $0.82 to $7.17.
Copyright 2014, Street Insider News Provided by Acquire Media Corporation
GPRK-got few more after reading this-- In Colombia, following our successful acquisitions of Winchester, Luna and Cuerva in early 2012, we have an asset base of 10 hydrocarbon blocks where we were able to increase average production to 6,075 boepd in the first nine months of 2013, an increase of 89% (on a pro forma basis, giving effect to our Colombian acquisitions) as compared to the first nine months of 2012. As of December 31, 2012, we had net proved reserves of 6.6 mmboe in Colombia. Furthermore, according to the D&M Brazil and Colombia Reserves Report, as of June 30, 2013, net proved reserves for certain new discoveries made in Colombia since December 31, 2012 resulted in an additional 2.4 mmboe of net proved reserves.
Read more: http://www.nasdaq.com/markets/ipos/company/geopark-ltd-805716-73454#ixzz2seknWjo0
GPRK-got few more after reading this-- In Colombia, following our successful acquisitions of Winchester, Luna and Cuerva in early 2012, we have an asset base of 10 hydrocarbon blocks where we were able to increase average production to 6,075 boepd in the first nine months of 2013, an increase of 89% (on a pro forma basis, giving effect to our Colombian acquisitions) as compared to the first nine months of 2012. As of December 31, 2012, we had net proved reserves of 6.6 mmboe in Colombia. Furthermore, according to the D&M Brazil and Colombia Reserves Report, as of June 30, 2013, net proved reserves for certain new discoveries made in Colombia since December 31, 2012 resulted in an additional 2.4 mmboe of net proved reserves.
Read more: http://www.nasdaq.com/markets/ipos/company/geopark-ltd-805716-73454#ixzz2seknWjo0
GPRK-IPO'ed today in the 6.00's original amount was 8.00 to 10.00 for 20 million shares now revised down 13.5 million shares in the 6.00's --maybe bargain??
GPRK-IPO'ed today in the 6.00's original amount was 8.00 to 10.00 for 20 million shares now revised down 13.5 million shares in the 6.00's --maybe bargain??
GPRK-radar-big oil gas just IPO'ed at 6.38---eom
GPRK-radar-big oil gas just IPO'ed at 6.38---eom
RSH-radio shack at 2.25-might breakout--40 million shorts---eom
RSH-radio shack at 2.25-might breakout--40 million shorts---eom
RSH-radio shack at 2.25-might breakout--40 million shorts---eom
RSH-radio shack-2.20 bottom-jmo--funding in place 2 months ago--closing 500 non performing stores---g/l
RSH-radio shack-2.20 bottom-jmo--funding in place 2 months ago--closing 500 non performing stores---g/l
RSH-radio shack-2.23--load point imho--eom
RSH-radio shack-2.23--load point imho--eom
RSH-loaded at 2.22--jmho--closing stores that are non performing is a big plus for them--g/l
RSH-loaded at 2.22--jmho--closing stores that are non performing is a big plus for them--g/l
NWHM-they build upscale homes-300k to 3.2 million in CA. they ipo'ed last friday-undervalued-jmho